Premium
Intra‐arterial Bleomycin therapy in inoperable squamous cell carcinomas
Author(s) -
Huntington M. C.,
Dupriest R. W.,
Fletcher W. S.
Publication year - 1973
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197301)31:1<153::aid-cncr2820310121>3.0.co;2-t
Subject(s) - medicine , bleomycin , leukopenia , stomatitis , basal cell , nausea , anorexia , erythema , chemotherapy , radiation therapy , gastroenterology , oncology , pathology , surgery
Twenty‐one patients with inoperable squamous cell carcinomas representing 12 sites of origin were regionally infused with intra‐arterial Bleomycin (BLM). Continuous infusions ranging from 20 mg to 525 mg total dose were given over 5‐day periods. There were three partial tumor regressions and two complete regressions lasting an average of 7 weeks. Side effects were minor and included fever (12/21), alopecia (9/21), stomatitis (8/21), anorexia or nausea (7/21), dermal vesiculation and erythema (6/21), and transient leukopenia (5/21). Noticeably absent among side effects was pulmonary fibrosis. Bleomycin infusions in our study caused short‐term but significant tumor regression in 5 of 21 patients with inoperable squamous cell carcinoma, while side effects were minor and less than with other methods of Bleomycin administration.